Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Merck Seeks To Build RNAi Muscle Through Artemis Partnership

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Deal calls for Germany-based Artemis to construct shRNA mouse models.

You may also be interested in...



AstraZeneca Gains Access To Silence siRNA Technology For Respiratory Targets

Company will use siRNA molecules against up to five targets in deal valued at up to $400 million.

AstraZeneca Gains Access To Silence siRNA Technology For Respiratory Targets

Company will use siRNA molecules against up to five targets in deal valued at up to $400 million.

Yes, Sirna: Merck Inks $1.1 Bil. Deal For RNAi Firm

Merck continues acquisition spurt with purchase of San Francisco biotech.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Ophthalmic Bevacizumab & CRISPR-Based Gene Therapy Among Latest EU Filings

Regulatory Flexibilities Help Ease EU Amoxicillin Shortages

Keeping Track: Two Targeted Oncologics And A Novel SGLT-2 Inhibitor Clear US FDA

US Medicare Price Negotiation: Gaming FDA Approval Dates Could Delay Drug Selection

See All
UsernamePublicRestriction

Register

PS063414

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By